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By

Lauren Thaxton
MD, MBA, MS

Introduction

The Institute of Medicine defines six important domains of health care quality:
safety, efficacy, timeliness, efficiency, equitable delivery and patient-centeredness.
Quality family planning care aims to provide individuals with the tools needed to engage
in healthy and satisfying sex lives while planning and spacing pregnancies to achieve
desired family size. The field of family planning strongly relies on the domain of patientcenteredness as individual values and preferences guide clinical care. Yet large gaps in
knowledge exist in understanding how to improve patients’ clinical experience. This
hybrid thesis posits avenues for improving the quality and patient-centeredness of clinical
care.
Quality care is meaningless if the public cannot access care. Numerous barriers to
health care exist in the US for many. Education about our bodies, confusing media
messaging about sex, cultural attitudes about sex and young parenting, conflation of
contraception with abortion in politics and Catholic hospital mergers create barriers to
access to care.
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On the other hand, a facilitator of access is an increase in comfort among
providers and patients with long acting reversible contraceptives or LARC.
Encompassing intrauterine devices (IUDs) and implants, LARC methods are highly
effective contraceptives that do not require ongoing adherence. These methods are
exploding in popularity, but can be difficult to obtain due to cost or difficulty obtaining
an appointment with a trained provider.
Extended duration of contraceptive implants may allow better contraceptive
coverage as women navigate access barriers. Additionally, IUDs can be painful to place
in the office setting. An anesthetic medication allowing an IUD to be placed with less
discomfort may empower women who might not otherwise feel comfortable with
placement of this method. Nitrous oxide is an inhaled gas that has been used in a number
of settings in medicine. As a novel agent for painful outpatient gynecologic procedures, it
provides the unique benefit of rapid clearance, potentially allowing a woman to obtain an
IUD under this rapidly reversible anesthesia and return to her daily activities. Nitrous
oxide may also preserve privacy, as other anesthetic options often require that a woman
have a driver following the appointment. Privacy is particularly important in provision of
abortion care.
These included chapters identify opportunities for the health care community to
improve quality per the Institute of Medicine’s domains.
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CHAPTER 1
Family Planning American Style Redux: Unintended Pregnancy Improves, Barriers
Remain
Because this is America. You’re supposed to pretend that you don’t notice certain
things.
—Chimamanda Ngozi Adichi, Americanah
INTRODUCTION
The rate of unintended pregnancy in the United States had been stagnant for
several decades, hovering around 50% to 51% of all pregnancies. That rate has finally
and definitively decreased. In the most recent cycle of the National Survey of Family
Growth (NSFG), a survey reported periodically by the Centers for Disease Control and
Prevention (CDC), the rate fell to 45% in 2011, compared with 51% in 2008 (1).
Rates of unintended teenage pregnancies, births, and abortions also have fallen.
From 2006 to 2014, teenage birth rates decreased 41% (from 41.1 to 24.2 per 1000
teenagers) (Fig. 1) (2). Reductions have occurred across all ethnicities, including African
American, Hispanic, and non-Hispanic white teenagers. The largest declines occurred in
Hispanic teenagers, followed by African American and non-Hispanic white teenagers.
Facilitating these changes are concerted efforts to address the social determinants
of teenage pregnancy, including review of community-level reproductive health data by
stakeholders, greater access to reproductive health services, and availability of teenagerfocused and culturally competent health education materials. Additionally, increases in
planned pregnancies are caused by improved access to and use of long-acting reversible
contraceptive (LARC) methods, top tier in contraceptive effectiveness (1).
Although rates of unintended pregnancy, teenage pregnancy, and abortion have
dropped dramatically, they remain higher than those for comparable countries in Western
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European countries. US rates are approximately twice those of France and Sweden (3).
Moreover, despite improvement, disparities persist in unintended and teenage pregnancy
among certain racial and ethnic groups. Black and Hispanic teenagers had higher
pregnancy rates (93 and 74 per 1000 teenagers) than non-Hispanic white teenagers (35
per 1000 teenagers) (2).
The larger picture goes beyond sexual health to broader social determinants. A
recent literature review revealed that socioeconomic factors at the individual and
community level, unrelated to sexual health, have a profound effect on teenage pregnancy
(4). Such factors as underemployment, inadequate income and education, and growing up
in a disadvantaged neighborhood at the low end of income inequality remind us that
solutions to teenage and unintended pregnancy require wide-ranging social change with a
focus on equity across the various domains.
This article discusses barriers to reducing unintended pregnancy, focusing on
societal obstacles to sexual health. Numerous factors may explain the higher rate in the
United States, including inadequate sexual education for adolescents, confusing messages
from the media, cultural attitudes about sex and young parenting, conflation of
contraception with abortion, burdensome contraceptive dispensing practices, and
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Fig. 1. US teenage pregnancy, birth, and abortion rates 1973 to 2011. (From Guttmacher Institute. U.S. teen pregnancy, birth and
abortion rates reached historic lows in 2011. Infographic. New York: Guttmacher Institute; 2016. Available at:
https://www.guttmacher.org/infographic/2016/us-teen-pregnancy-birth-and-abortion-rates-reached-historic-lows-2011; with
permission.)

reduced access to health care caused by lack of insurance or hospital mergers. Yet
several facilitators can counteract these factors, expanding access to reproductive health
care. Local communities and society at large should pursue progressive strategies as a
public health priority.

INFLUENCE OF SEXUALITY EDUCATION ON UNINTENDED PREGNANCY
Sexuality education remains a battleground. Beginning in the 1980s and
increasing substantially with welfare reform in 1996, significant federal funding
promoted abstinence-only-until-marriage education. The federal/state matching program
mandated that states receiving federal funding would provide sexuality education that
met strict criteria, complying with an eight-item definition of abstinence-only education.

3	
  

Thaxton

4	
  

The goal of this curriculum is to persuade young people to abstain from sexual activity. It
teaches that abstinence is the only certain way to avoid pregnancy and sexually
transmitted infections; that sexual activity outside marriage is likely to have harmful
psychological and physical effects; and that a mutually faithful, monogamous
relationship in the context of marriage is the expected standard of human sexual behavior
(5).
The Obama administration’s intent was to end most abstinence-only education
programs in favor of comprehensive sexual education, but Congress reinstated $250
million of federal funding for abstinence-only education over a 5-year period. During the
last 10 years, taxpayers have supported abstinence-only education programs for
adolescents at a cost of more than a billion dollars (6).
Abstinence-only sex education has been extensively evaluated using such
outcome measures as sexual debut, number of sexual partners, effectiveness of virginity
pledges, acquisition of sexually transmitted diseases (STDs), and use of contraceptives at
first sex. Current research suggests not only that abstinence-only education is ineffective,
but also that parents overwhelmingly support comprehensive sex education (7).
Comprehensive sex education that includes abstinence, contraception, and STD
prevention seems to optimize reproductive health outcomes (8–10). Abstinence only
education can do harm: for example, studies of virginity pledges, a common component
of several popular abstinence-only education programs, suggest that although pledgers
are just as likely to have premarital sex as nonpledgers, they are less likely than
nonpledgers to avail themselves of contraception or STD protection (11) A recent
Cochrane review published through the Cochrane Database of Systematic Reviews
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concluded that educational and contraceptive-promoting interventions reduce unintended
pregnancy in adolescents (12).

Evidence strongly supports comprehensive sex education. In 2010 funds became
available under the Patient Protection and Affordable Care Act (ACA) for scientifically
sound programs that draw on curriculum-based sex education or youth development
approaches to prevent teenage pregnancy. Despite mounting evidence of the benefits of
comprehensive sex education, the young are less likely today than they were in 1995 or
between 2006 and 2010 to receive instruction on contraception (13). Healthy People 2020
data show a decrease in the percentage of women and men younger than 18 given formal
instruction about contraceptive methods. Compared with responses from the 2006 to
2010 period, responses from 2011 to 2013 showed a drop in reported formal birth control
education for women from 70% to 60% and for men from 61% to 55% (13). This
reduction is not surprising given the keen focus and massive funding dedicated to
abstinence-only sex education over three decades. At coital debut, 79% of female
teenagers and 84% of male teenagers used a contraceptive method. Less effective
methods, such as condoms, remain the most common contraceptive choice in this age
group (14).
Amid debates on the merits of abstinence-only-until-marriage education versus
comprehensive sex education, oddly no federal requirements for the content of sexuality
education exist. Some states have created requirements for sex education and human
immunodeficiency virus (HIV) prevention but curricula vary widely between states (15).
Whereas 24 states mandate sex education and 18 require information on contraception,
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37 states mandate information. Eighteen states require information on contraception and
13 states require that the instruction be medically accurate.
Yet overall despite some state requirements, an analysis of NSFG data showed
declines in receipt of formal sex education and disparities between rural and urban areas;
adolescents living in nonmetropolitan areas were significantly less apt to obtain
instruction in such topics as abstinence, birth control, and STD prevention (16).
Ironically, despite the inconsistency of sexuality education in the United States,
over time some positive changes in teenage sexual activity have occurred (17,18). From
1995 to 2011 to 2013, fewer teenagers younger than age 15 had become sexually active.
From 1982 to 2011 to 2013, more teenagers used contraception at first sex (48% vs 79%).
Reductions in formal comprehensive sex education have occurred over the same time
period that has seen a drop in teenage birth rates.
Teenagers do not seem to receive additional information from other sources, such
as parents or friends; as for social media, its effect is unknown. Although teenage
pregnancy rates are lower, widespread adoption of comprehensive sex education has the
potential to reduce these rates further. Additionally, a host of professional organizations,
including the Society for Adolescent Medicine, the American College of Obstetrics &
Gynecology, and the American Pediatrics Association strongly support comprehensive
sexuality education, including refusal skills, abstinence, and contraception. The American
Academy of Pediatrics (AAP) offered testimony to the House Committee on Oversight
and Government reform on behalf of its membership and that of the American Society of
Adolescent Medicine, urging funds for comprehensive sex education (19).
The CDC Healthy People 2020 goals incorporate sexuality education goals,
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including increasing the percentage of females younger than 18 who receive formal
instruction in birth control to 78%, and the percentage of males younger than 18 to
67%. These targets are in alignment with the evidence of the near universality of
premarital sex, and of sexual debut by more than half of all women and men by age
18 (17,18). Although age at sexual debut has decreased, common sense dictates that
the provision of information for most teenagers who do have sex is bound to have a
positive impact on unintended pregnancy and on STD acquisition.

INFLUENCE OF MEDIA ON UNINTENDED PREGNANCY
A disconnect remains between the halting steps toward comprehensive sexuality
education and current content of many forms of media, saturated with sex. Although the
United States has not embraced comprehensive sexuality education for youth, it has
thoroughly adopted the use of sex for advertising a wide range of products. Sexual
content also figures large in a range of television shows, from sit-coms to reality
television and little of that content conveys messages about responsible sex, including
monogamy or safe sex (20). This schizophrenic approach—to deny in the classroom what
is sold in the marketplace—seems distinctly American. We refuse to engage with young
people in serious conversations about sex, conversations that could help prevent
unwanted pregnancy and STDs and help youth better understand how sexuality may
contribute to well-being. Pervasive American morality seems at odds with accepting
sexuality as a normal part of human behavior. This leaves many individuals, but
particularly youth, confused, with a double standard that creates obstacles to the
avoidance of unintended pregnancy.
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Americans spend considerable “screen time” between television, mobile devices,
and computer use. In 2013 a comprehensive survey studied teenage media use. Two
media activities dominated: television and music. The survey found that teenagers use an
average of 9 hours of media every day. Those from low-income families use media for
considerably more time than teenagers from higher-income families (21). For “screen”
media, lower-income teenagers averaged 8.07 hours a day, whereas higher-income
teenagers averaged 5.42 hours.
The potential impact of sexual content on television is important, given the great
amount of time Americans spend watching television. In 1998, a total of 56% of
television shows contained sexual content, with an average of 3.2 scenes per hour. By
2005, the percentage of shows that included sexual content increased to 70%, with
an average of five scenes per hour (20). Although the Kaiser Family Foundation no
longer studies the sexual content of television shows, the Parents Television Council,
continues to watchdog content. The Parents Television Council issued a report finding
that sexual references in shows had increased by 22% (22).
Evidence is conflicting regarding the impact of television’s sexual content on the
sexual behavior of teenagers, although numerous studies attest to the influence on
teenagers’ attitudes toward sex and on their values and beliefs. A recent study of
youth aged 12 to 17 demonstrated a higher likelihood of teenage pregnancy in the
3 years following frequent exposure to television’s sexual content including a mix of
dramas, comedy, reality, and animated programming (23). Teenage pregnancy in the
high-exposure groups was twice the rate of the low-exposure group, even after
adjusting for confounders. Most evidence seems to support an association between

Thaxton
more frequent and more sexually explicit viewing as a risk factor for unsafe sexual
behavior. These associations led the AAP to publish a strongly worded policy statement
directed at pediatricians and the entertainment/broadcast industry (24). Among the
recommendations were these: counseling parents to be aware of and limit teenagers’
screen time, encouraging the entertainment industry to produce more programming with
responsible sexual content, and urging the broadcast industry to expand airtime for
advertising of contraceptives.
Media can also have a positive impact. Several television programs have
incorporated positive health-related messaging. Gray’s Anatomy and ER dramatized
story lines that educated the public about human papilloma virus, emergency
contraception, and HIV. In an innovative trial involving social media, messaging was
used to increase condom use among at-risk youth. The results showed some evidence of
effectiveness (25). As urged by the AAP, expansion of contraception advertising could
have a positive effect on reducing unintended pregnancy. Lack of or highly restricted
advertising for contraceptives has been the norm. In the United Kingdom, the AIDS
epidemic prompted networks to allow condom advertisements in primetime, rather than
confine them to an after 9 PM time slot (26).
Overall, however, the combination of explicit sexual content in media with
limited “responsible” sexuality content or contraceptive advertising constitutes a barrier
to reducing unintended pregnancy. Disparities in the consumption of media by lower
income youth may result in additional negative consequences.

CULTURE AND FAMILY PLANNING
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Cultural norms may result in unconscious bias that perpetuates negative
stereotypes of minority women. In 2011, the birth rate for non-Hispanic white teenagers
(21.7 per 1000) was less than half that among non-Hispanic black teenagers and Hispanic
teenagers (at 47.2 and 49.6 per 1000, respectively) (Fig. 2) (27). This disparity mirrors
broader disproportionately adverse health care outcomes occurring within communities
of color. Many well-intentioned reproductive health interventions have therefore
“targeted” specific communities for an intensive focus on reducing unplanned pregnancy,
a practice that can lead to unintended consequences.
Standard expectations for “acceptable” parenting, including age at first birth,
family size, and intention to become pregnant, are set by the dominant culture (28).
Members of the dominant culture, high income non-Hispanic whites, are overrepresented
in medicine and largely responsible for the reproductive health counseling of young
women. Lack of appreciation of the power differential between patient and provider, and
cultural biases can unintentionally result in reproductive coercion toward use of
contraception and use of specific methods and moral condemnation for reproductive
choices and outcomes (29–31). Although access to contraception may decrease
pregnancy, birth, and abortion rates, social determinants may be much more powerful
mediators of high birth rates in communities of color. These social determinants involve
several inequities experienced daily by members of the non-dominant culture (4). Health
care providers must focus on providing knowledge and access to full-spectrum
contraceptive options so that women and men are able to make autonomous, well
informed choices grounded in a shared decision-making model.
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ACCESS TO CARE: THE IMPACT OF THE AFFORDABLE CARE ACT
Almost every American woman will use a method of contraception at some point
in her life (99%). The average American woman spends 30 years preventing pregnancy
(32). Numerous publications appropriately emphasize the cost savings of contraceptive
insurance coverage. But even when contraception is “covered,” lack of adequate
insurance coverage, such as high out-of-pocket costs in the form of copays and
deductibles, is a barrier to the affordability of desired methods.

Fig. 2. Birth rates for females aged 15 to 19 years during 2006 to 2014. (From Romero L, Pazol K, Warner L, et al. Reduced
disparities in birth rates among teens aged 15–19 years— United States, 2006–2007 and 2013–2014. Morb Mortal Wkly Rep
2016;65:411. Available at: http://www.cdc.gov/mmwr/volumes/65/wr/mm6516a1.htm?version5meter1at1null&
module5meter-Links&pgtype5article&contentId5&mediaId5&referrer5&priority5true&
action5click&contentCollection5meter-links-click. Accessed August 8, 2016.)

The most highly effective reversible methods, intrauterine devices (IUDs) and
implants, have high up-front costs despite their long-term cost-effectiveness. In the
2012 NSFG, 11.6% of women reported use of an IUD or implant (33), a major increase
from the prior reporting period, but considerably less than the uptake in many studies of
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LARC. In the Contraceptive CHOICE study, a large cohort trial conducted in St. Louis,
Missouri, 75% of women chose an IUD or implant for contraception when women were
offered all methods without financial barriers (33).
To address the national health care delivery crisis, in 2010 President Obama
signed the ACA into law. Based on recommendations from the Institute of Medicine (34),
the Health Resources and Services Administration mandated coverage of “Food and Drug
Administration approved contraceptive methods, sterilization procedures, and patient
education and counseling for women with reproductive capacity” with at least one form
of each type of contraceptive covered without cost sharing (35)

The impact of the ACA was swift: the proportion of reproductive-aged women
who were uninsured fell by 40%. Many women for the first time were able to afford their
desired contraceptive method. The number of women who filled prescriptions for birth
control pills with no copay exploded, from 1.2 million in 2012 to 5.1 million in 2013
(36). Nationwide claims database research reveals that from 2011 to 2013, the mean
copay per contraceptive claim decreased 73%, from $15 to $4. Additionally, the number
of commercially insured women with $0 out-of-pocket cost for any contraceptive
increased from 10.1% in 2011 to 69.6% in 2013 (37). In 2014, a total of 87% of insured
women were able to obtain an IUD without out-of-pocket costs (Fig. 3 data from the
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Fig. 3. The Affordable Care Act contraceptive mandate has made contraception more financially attainable for insured women. (From
Guttmacher Institute. The Affordable Care Act is working. Infographic. New York: Guttmacher Institute; 2016. Available at:
https://www.guttmacher.org/infographic/2015/affordable-care-act-working; with permission.)

Guttmacher Institute) (32). By reducing out-of-pocket costs for insured women, the ACA
contraceptive mandate has made contraception more financially attainable.

ANTICONTRACEPTIVE POLITICS
Since its inception, the contraception mandate has been mired in religiously
motivated activism and anticontraception politics. A vocal minority holds that
contraception promotes societal problems, such as promiscuity, an antichild attitude, and
the undermining of traditional male-female relationships (38). Until recently, most
experts agreed that improved contraceptive use was a major component in efforts to
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decrease abortion. A more radical view is that the provider of contraception violates
morality. The Catholic doctrine that “every “marital sexual act must be open to the
possibility of the transmission of life,” (39) is not supported by the reality that almost all
Catholic women have used contraception during their lives (40). Deplorably, scientific
misinformation about the mechanism of action of many contraceptives has led
antiabortion activists to oppose several contraceptives. Increasingly, contraception and
abortion politics are polarized, partisan topics (41).
In February 2012, the Republican-led House Oversight and Government Reform
Committee organized a hostile review of the ACA contraceptive mandate, claiming it to
be an “assault against their freedom of conscience.” (42) Specifically, House members
asserted that the contraceptive mandate violated the religious freedoms of certain
employers whose faith teaches the immorality of contraception. The panel was
exclusively composed of male theologians and clergy hearing testimonials from
adherents of religious organizations and institutions.
Democratic members of the Committee requested the addition of Georgetown law
student, Sandra Fluke, to the list of witnesses. Ms. Fluke had firsthand experience of the
difficulties in seeking reproductive health care at a religious university. The Committee
Chairman, Darrell Issa, denied the request on technical grounds, adding that Ms. Fluke
lacked sufficient experience. Chairwoman Nancy Pelosi then convened a meeting of the
Democratic Steering and Policy Committee and offered Sandra Fluke
the opportunity to testify. Her testimony outlined the personal experiences of women
enrolled at Georgetown University who were unable to obtain full spectrum health care
because of the faith-based limitations of their insurance coverage.
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Ms. Fluke and her testimonial were criticized by political commentator Rush
Limbaugh in his radio talk show. He called Fluke a “slut” and a “prostitute” stating that
“she’s having so much sex she can’t afford her own birth control pills.” Although
mainstream media condemned his misogyny, “slut shaming” remains a tactic used by
conservative thought leaders to shut down discussion of the contraceptive mandate. The
acrimony of the conservative response to Ms. Fluke reflects the increasingly controversial
nature of contraception.
In 2012, the Green family, Evangelical Christian owners of the arts and crafts
business, Hobby Lobby, dropped coverage of two types of contraceptives (IUDs and
emergency contraception pills). They brought suit against the government asserting
that the mandate interfered with their religious freedom, citing the Religious Freedom
Restoration Act. The Green family defined IUDs and emergency contraception pills as
abortifacients, counter to the medical definition of abortifacients, which act after
implantation. The US Supreme Court accepted the case in Burwell v. Hobby Lobby; in a
landmark decision, the Court ruled that closely held for-profit corporations could
file for a religious exemption to the contraceptive mandate. As Justice Ruth Bader
Ginsburg pointed out in her dissent, “the court, I fear, has ventured into a minefield.”
The implications of this decision are broad insofar as they conflate a critical public
health prevention strategy and the interests of women’s health with a violation of
religious freedom.

HOSPITAL MERGERS
A systems barrier to reducing unintended pregnancy is the negative impact on
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reproductive health services that occurs when nonsectarian hospitals merge with
religious, particularly Catholic, hospitals. In the 10 years from 2001 to 2011, the number
of Catholic hospitals increased 16%, more than any other type of nonprofit hospital (Fig.
4). Ten of the largest 25 health systems in America are Catholic (43). In 2016, one in
every six acute care hospital beds is in a Catholic owned or Catholic affiliated hospital
(44).
These mergers mean that more and more Americans are being treated in Catholic
facilities, which operate under the explicit requirements embodied in the Ethical and
Religious Directives (ERDs) for Catholic Health Care Services (45). Among other
services, these directives explicitly oppose abortion, family planning, sterilization of men
and women, emergency contraception, and HIV counseling that includes information
about condom use. Mergers between nonsectarian and Catholic hospitals often result in
the elimination or severe restriction of reproductive health services. In some states, a
Catholic owned or affiliated hospital may be the only local hospital.
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Fig. 4. Percentage change in number of acute-care hospitals by hospital type from 2001 to
2011. (From Uttley L, Reynertson S, Kenny L, et al. Miscarriage of medicine: the growth of Catholic hospitals and the threat to
reproductive health care. American Civil Liberties Union and the MergerWatch Project. 2013. Available at:
https://www.aclu.org/report/miscarriagemedicine. Accessed August 9, 2016; with permission. Courtesy of MergerWatch and the
ACLU. Artist: Brucie Rosch.)

The impact of the ERD restrictions on reproductive health care should not be
ignored. Public activism is a successful strategy. The National Women’s Law Center
developed the Health Care Provider Merger Project, which uses legal tools to focus
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attention on the ERD restrictions at the local level (46). The American Civil Liberties
Union recommends national activism to press for investigation into Catholic hospitals
for violation of Centers for Medicare and Medicaid Services requirements that
all hospitals provide emergency health care regardless of religious affiliation. On
an individual level, the American Civil Liberties Union encourages patients to learn
whether or not their local hospitals are Catholic run or affiliated and which services
are offered (47).

WHO IS MOST AFFECTED?
Despite the advances in access because of the ACA, certain groups remain at a
disadvantage. Objections to ACA coverage of contraception disproportionately affect
women already at risk for gaps in coverage including minors, women of color, and
women residing in Medicaid nonexpansion states (48).
Despite professional societies’ recommendations to routinely offer highly
effective methods, such as IUDs and implants, to adolescents and young women as firstline contraception (49), uptake remains low. Some postulate that confidentiality may
drive nonuse because some states require parental notification of contraceptive services.
A 2003 to 2004 survey finds one in five adolescents stating that if faced with mandatory
parental notification laws, they would use not contraception at all or rely on withdrawal
(50). Where parental notification is not mandated, teenagers enrolled in their parents’
health plans may nevertheless fear loss of confidentiality via explanation of benefits or
copays.
Latina women are also less apt to have adequate coverage for reproductive health
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services despite the ACA. Compared with white women, Latinas have twice the odds of
being uninsured and this discrepancy is even more stark among immigrant Latina women
(Fig. 5) (51) These statistics indicate that institutional and policy barriers are major
obstacles to contraception for women of color.
As of July 2016, a total of 19 states have chosen to opt out of Medicaid expansion
under the ACA including Alabama, Florida, Georgia, Idaho, Kansas, Maine, Mississippi,
Missouri, Nebraska, North Carolina, Oklahoma, South Carolina, South Dakota,
Tennessee, Texas, Utah, Virginia, Wisconsin, and Wyoming (Fig. 6) (52). In these states,
women had twice the odds of being uninsured after implementation of the ACA.

FACILITATORS
Although many barriers impede access to family planning services, the last
decade has also seen a resurgence of facilitators promoting women’s ability to
successfully plan their families. Providers have become more comfortable with an
expanded candidate profile and with the techniques for placement of IUDs and implants.
The American College of Obstetricians and Gynecologists recommends an expanded
profile of candidates thought appropriate for IUDs, including adolescents and nulliparous
women (53). Using a model of shared, nondirective decision making, providers are
encouraged to review with patients their reproductive health goals and the range of
methods for achieving them.
The American College of Obstetricians and Gynecologists supports other access
facilitators, such as same-day initiation of methods, no unnecessary additional medical
appointments, and no required pelvic examinations or STD testing before receipt of a
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method (54). Medically unnecessary steps create a heavier burden for women seeking

Fig. 5. Latina women are less apt to have adequate coverage for reproductive health services despite the ACA. Statistics indicate that
institutional and policy barriers are major obstacles to contraception for women of color. Notes: Poor women are those in families
with incomes under the federal poverty level ($20,090 for a family of three in 2015). Data include some information on undocumented
immigrants, although that information is generally acknowledged to be a considerable undercount of that population group. (From
Guttmacher Institute. Immigrant women need health coverage, not legal barriers. Infographic. New York: Guttmacher Institute; 2016.
Available at: https://www.guttmacher.org/infographic/2016/immigrant-women-need-health-coverage-not-legal-barriers; with
permission; and Special tabulations of date from the 2016 American Community Survey (data are for 2015).)
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Fig. 6. As of July 2016, 19 states have chosen to opt out of Medicaid expansion under the
ACA. Note: Current status for each state is based on KCMU tracking and analysis of state executive activity. a AR, AZ, IA, IN, MI,
MT, and NH have approved Section 1115 waivers. WI covers adults up to 100% FPL in Medicaid, but did not adopt the ACA
expansion. FPL, federal poverty level; KCMU; Kaiser Family Foundation’s Commission on Medicaid and the Uninsured. (From
Status of state action on the Medicaid expansion decision. The Henry J. Kaiser Family Foundation. Available at: http://kff.org/healthreform/slide/current-status-ofthe-medicaidexpansion-decision/. Accessed August 9, 2016.)

contraception. Another principal facilitator is over-the-counter status for oral
contraceptive pills (55). The greatest risk of oral contraceptives is venous
thromboembolism; the argument for over-the-counter status is the rarity of the outcome
(3–10.22 per 10,000 women years) compared with the considerably higher risks of
pregnancy. Some states, such as California and Oregon as well as Washington and New
Mexico now, have passed legislation allowing pharmacists to prescribe oral
contraceptives (56). Immediate postpartum insertion of highly effective LARC methods
is also gaining in popularity. The postpartum window is an ideal time for contraception
because the patient is known not to be pregnant and she has ease of access to medical
professionals (57,58). In several states, Medicaid has allowed the uncoupling of the
global delivery fee from the LARC device and insertion, permitting hospitals to offer this
service.

SUMMARY
In 2015, Latin America saw the spread of the mosquito-borne Zika virus. This
disease, although typically asymptomatic, is known for the microcephalic babies born to
women infected during pregnancy. In the summer of 2016, for the first time, the CDC
issued a travel warning to a local city, Miami, Florida, because of a cluster of new cases
(59). The spread of the virus has forced the discussion of reproductive health care in
America and of the real-life impact that restrictive family planning and abortion policies
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create. Although many health experts have indicated that women exposed to the virus
should not get pregnant for at least 8 weeks following infection, few policies have
translated into actionable plans to meet these reproductive health goals. Systems
approaches that focus on education and access to care are critical (60,61). The ability to
prevent the devastating consequences of infection depends on making family planning
services available to all. Availability is ineffective without education and education alone
is insufficient without policy change.
Contraception has become a new political battle ground across the United States
and in the nation’s capital. American women and families are the victims of this battle;
politicization of abortion and contraception harms Americans seeking access to basic
health care. Promotion of contraception should occur at every level, from early and
comprehensive sexual education to responsible media. Recommendations of religious
leaders and politicians should not supersede those made by leagues of health
professionals.
Accomplishing health equity starts by recognition that disparities exist.
Disparities in reproductive health outcomes based on socioeconomic status and
race/ethnicity are compounded by the controversial nature of reproductive health care
services. Society’s reluctance to accept the reality and impact of reproductive health care
needs widens the equity gap. In health care, it is time that Americans turn the spotlight on
reproduction. So long as reproductive health care is deemed exceptional or outside of the
purview of medicine, Americans will continue to suffer the consequences.
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CHAPTER 2
Efficacy of Extending Contraceptive Implant Duration: A Systematic Review
Introduction
Progestin-only implants are highly effective contraceptive methods with less than
1% of women experiencing an unintended pregnancy in the first year of use (1)(2)(3).
Women of all ages are interested in the contraceptive implant because of its long duration
of action, reversibility and efficacy (4)(5)(6)(Kennedy C., Values and preferences in
contraceptive decision making: a systematic review, unpublished data submitted for
publication, 2017). Implants can also be highly cost effective (7)(8). Contraindications to
implants are uncommon due to the lack of an estrogen component (9). Implants exhibit
high continuation rates and represent an increasing proportion of the contraceptive
method mix.
Implants have three probable mechanisms of action: suppression of ovulation,
thickening of cervical mucus, and endometrial atrophy (3). Two subdermal progestin
implants are currently available globally: etonogestrel (ENG)-releasing (including the
Implanon® and Nexplanon®) and levonorgestrel (LNG)-releasing (including the SinoImplant II and Jadelle®) devices (10)(11). The description for each of these devices is
included in Table 1.
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Table 1: Description of Devices
Device
Brand
Names
Nexplanon,
Implanon
Sino-Implant
(II),
Levoplant,
Femplant,
Trust, Zarin
Jadelle

Manufacturer

Progestin

Rod

Recommended
Duration of
Use
(years)

Merck

68 mg ENG

1

3

Shanghai Dahua
Pharmaceuticals
Co., Ltd
Bayer

75 mg LNG
75 mg LNG

2
2

4
5

Despite benefits, barriers to obtaining a progestin-only implant are reported
among women who desire them, including access to trained professionals for placement
and removal and high up front device costs. Efforts have been made to take advantage of
convenient opportunities for placement, such as immediately post pregnancy (12).
Extending the duration beyond the currently approved length of use, if shown to be
efficacious, could offer another means to enhance accessibility by maximizing the lifetime of the implant.
The purpose of this systematic review was to examine current evidence to answer
the question “Can the use of contraceptive implants be extended beyond currently
approved durations without compromising contraceptive efficacy?”

Sources
We searched published studies among PubMed and EMBASE, as well as ongoing
clinical trials registered on CT.gov and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP). To locate articles within
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PubMed and EMBASE, we used the following search terms for devices, developed
together with a Health Science Librarian: “levonorgestrel”, “norplant”, “Jadelle®”,
“etonogestrel”, “Implanon®”, “Nexplanon®” and “sino implant” as well as search terms
for pregnancy outcomes (to assess contraceptive failure) and study designs including
clinical trials or cohort studies. This resulted in the following search strategy for PubMed:
"Pregnant Women"[Mesh] OR " Pregnancy"[Mesh] OR " Pregnancy
Complications"[Mesh] OR "Maternal Health Services"[Mesh] OR "Mothers"[Mesh] OR
"Maternal Death"[Mesh] OR "Maternal-Fetal Relations"[Mesh] OR "Maternal
Exposure"[Mesh] OR "Maternal Mortality"[Mesh] OR "Maternal Behavior"[Mesh] OR
pregnan* [TIAB] OR Maternal*[TIAB] OR mother*[TIAB] OR child bearing [TIAB]
OR perinatal [TIAB] OR Postnatal[TIAB] OR peri-natal [TIAB] OR post natal [TIAB]
OR ante natal [TIAB] OR antenatal [TIAB] OR Postpartum [TIAB] OR puerperium
[TIAB] OR post partum [TIAB] OR abortion* [TW] OR abortive [TW] OR "Abortion,
Induced"[Mesh] AND (Animals [MH] NOT (Humans [MH] AND Animals[MH])) AND
"randomized controlled trial"[pt] OR "controlled clinical trial"[pt] OR "clinical trials as
topic"[mesh] OR "random allocation"[mesh] OR "double-blind method"[mesh] OR
"single-blind method"[mesh] OR "clinical trial"[pt] OR "research design"[mesh:noexp]
OR "comparative study"[pt] OR "evaluation studies"[pt] OR "follow-up studies"[mesh]
OR "prospective studies"[mesh] OR "cross-over studies"[mesh]OR "clinical trial"[tw]
OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw]) AND (mask*[tw] OR blind*[tw])) OR
placebo*[tw] OR random*[tw] OR "control"[tw] OR "controls"[tw] OR prospecitv*[tw]
OR volunteer*[tw] OR "cohort studies"[mesh] OR "case-control studies"[mesh] OR
"comparative study"[pt] OR "risk factors"[mesh] OR "cohort"[tw] OR "compared"[tw]
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OR "groups"[tw] OR "case control"[tw] OR "multivariable"[tw] AND
("levonorgestrel"[MeSH Terms] OR levonorgestrel[All Fields] OR norplant[All Fields]
OR Jadelle®[All Fields] OR ("etonogestrel"[MeSH Terms] OR etonogestrel[All Fields]
OR Implanon®[All Fields] OR Nexplanon®[All Fields] OR “sino implant” [TW]).
Articles published between January 1, 1996 and December 31, 2016 were
included as FDA approval of the Jadelle® implant occurred in 1996 and all other devices
were developed and released after this year. The search was not restricted with regards to
country or language. To identify studies within ClinicalTrials.gov and ICTRP we used
the following search terms: “levonorgestrel”, “norplant”, “Jadelle®”, “etonogestrel”,
“Implanon®”, “Nexplanon®” and “sino implant” with participants limited to female
children and adults.

Study Selection
We included studies investigating the contraceptive effectiveness of extended use
of levonorgestrel or etonogestrel implants beyond current approved durations. Studies
evaluating the Norplant® were excluded as this device is no longer available.
Additionally, studies evaluating contraceptive implants currently in pre-marketing trials
were not included. Inclusion criteria included randomized clinical trials (RCTs), cohort or
case-control studies with some measure of contraceptive efficacy of one of the four
devices specified beyond the currently approved duration. Conference abstracts, posters
or oral presentations were excluded. Studies included from ClincalTrials.gov were
eligible if they investigated one of the two etonogestrel implants, Implanon® or
Nexplanon® as these implants are the only available in the United States. For ongoing
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trials, we contacted corresponding authors to determine if any data could be included in
this review.
The title and abstract from each article was evaluated by two independent
reviewers to determine if the article met inclusion/exclusion criteria. The full text of the
article was obtained if both reviewers judged a citation as potentially eligible; full text
was screened for eligibility by both reviewers. No discrepancies were noted. Reasons for
exclusion, including number of duplicates, were documented. Reviewers abstracted the
following information from the remaining articles: study title, author and publication
year, funding source, study design, population size, duration of extended use, type of
implant and number of contraceptive failures. Using the United States Preventative
Services Task Force guidelines, each article’s study quality was rated as “poor”, “fair” or
“good” (13). This rating was based on methodological quality rating as assessed by
reviewers along the following domains: assembly of appropriate comparison groups
(including adequate description and execution of randomization in RCTs and assessment
of potential confounders in cohort studies such as participant age), loss to follow up
during the study and description of how pregnancy was assessed. Additionally, quality of
data analysis and interpretation was assessed according to whether adjustments were
performed for confounders and whether contraceptive efficacy was measured
cumulatively or analysed separately among women beyond approved duration.

Results
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Figure 1: CONSORT Diagram
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We identified 439 ongoing clinical trials and, of these, selected 4 studies for
further review based on published information on Clinical Trials.gov or ICTRP (Figure
1) (14). One study was complete, two active and not recruiting, and one was still
recruiting (15)(16)(17)(18). We contacted primary investigators to obtain data where
available. The single ongoing study published interim findings in January of 2017. In this
prospective cohort study, 291 women using the ENG implant extended by two years: 223
(77%) used the method for greater than 12 additional months, and 102 (35%) for greater
than 24 additional months. These women represented a diversity of BMIs with 23%
overweight and 52% obese or morbidly obese. In total, study participants contributed 444
women-years of follow up with no documented pregnancies for a calculated five year
Pearl Index of 0 per 100,000 women-years (18).
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We identified 2,326 citations in the published literature and selected 23 articles
for full-text screening after review of titles and abstract (Figure 1). Sixteen studies were
excluded because they did not meet inclusion/exclusion criteria. One additional study was
removed from the analysis as it represented a secondary publication and did not offer new
data (19). Another article was removed as the data appeared to have been previously
published and subsequently retracted in another journal due to erroneous data (20) (21).
We included six studies in this systematic review resulting in a total of 1,357 women who
self selected extended duration of their contraceptive implant (22)(23)(24)(25)(26) (27)
(Table 2). Five studies evaluated the single-rod ENG implant (Implanon®), one evaluated
the LNG implant, Jadelle®. No studies evaluated the Sino-Implant or Nexplanon®
however, the Nexplanon® is simply a newer generation of the Implanon® with the same
dose of ENG and pharmacokinetic properties. Four studies were sponsored by the
manufacturer of the single-rod ENG implant. Only two studies separately evaluated
contraceptive failure over the time frame of extended duration rather than cumulative use
of the implant (23)(22).
The only RCT identified was part of a larger, multi-country study of healthy
women desiring long-acting reversible contraception. Importantly, women were
randomized to the type of contraception, single-rod ENG implant versus the 2-rod LNG
implant, not the duration of use; women self-selected extended duration of the implant.
Contraceptive failures were compared with a non-randomized control group of women
who received the TCu380A Copper IUD (Pregna ®). A subset (N=390) of women
randomized to the single-rod ENG implant consented to extended duration of use; 204
women completed five years of use (47% loss to follow up) with no reported pregnancies
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for a calculated Kaplan-Meier cumulative pregnancy rate of 0.6 per 100 women-years
(95% CI 0.2-1.8). Women randomized to the ENG versus the LNG implant noted similar
side effects including irregular bleeding; users of the ENG implant exhibited higher rates
of self-reported heavy menstrual bleeding. Removal time for the 1-rod ENG implant was
additionally noted to be shorter in comparison to the 2-rod LNG implant (22).
The five remaining studies were prospective cohort in design. One study recruited
women from a larger parent study of long-acting reversible contraception in St. Louis,
USA. The parent study offered healthy, reproductive aged women desiring contraception
access to contraceptive methods free of charge. Most participants elected use of an
intrauterine system (IUS) or ENG implant (28). Those who consented to extending
duration of their implants were followed and results of data collected during extension
are reported here; this represents an interim analysis as recruitment and follow-up were
ongoing at the time of publication. A total of 237 women consented to extended duration
of their implant; 123 completed the fourth year and 34 completed the fifth year.
Participants represented a broad range of body mass index (BMI); 42 (46%) were obese
or morbidly obese. No pregnancies were reported during the follow up period.
Additionally, 47 participants contributed to ENG serum analysis data at the fourth year,
revealing a median ENG level of 170.0pg/ml (Range: 67.9, 470.5) with no differences
across BMI groups (23).
All other studies evaluated contraceptive failures cumulatively over the entire use
of the implant. A comparative study conducted in China examined women with extended
use of the ENG implant and women using the 6-rod LNG implant. Among the 75
participants who received an ENG implant, 51 completed four years of use (32% loss to
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follow up) with no reported pregnancies. Side effects included change in bleeding
pattern, headache, breast tenderness and cramping. Additionally, women experienced a
small increase in weight (3.5kg) and hemoglobin concentration, but no change in blood
pressure (27).
Three of the studies were cohort studies, without a comparison group, evaluating
women with extended use of the ENG implant for one year. No pregnancies were
reported in any of these studies, although sample sizes were small for women completing
the fourth year of implant use (N= 47 to 151) and loss to follow up was high. The most
common reasons for discontinuations were desire to conceive or abnormal uterine
bleeding; number of bleeding-spotting days was highest in the first few months of use.
There were no changes in cervical cancer screening, hemoglobin levels or blood pressure.
Small increases in weight occurred over study duration (1.1 to 2.9 kg). Insertion and
removal times were short (less than five minutes) and return to fertility was rapid after
implant removal (20)(25)(26).
A single study evaluated extended duration of the 2-rod LNG implant. A noncomparative prospective cohort study, it recruited 249 women to extended use of the
LNG implant by one year. Only 58 women completed the additional year of use (77%
loss to follow up); five women did not return for follow up for three or greater years.
There were three diagnosed pregnancies in this study: one pregnancy was diagnosed prior
to insertion of the implant and this participant was removed from analysis. A second
pregnancy was diagnosed within the first month of implant use; the authors considered it
likely a luteal phase pregnancy. The third pregnancy was diagnosed in the first year of
extended duration (in the sixth year of use). The most common reason for early removal
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of an implant was desire to conceive; implant removal times were shorter for the 2-rod
LNG implant compared to historical times for removal of the 6-rod LNG implant (24).

Table 2: Summary of Included Studies
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Author, Year

Title

Study design

Study Size

Exposure

Peal Index

up to 1 year
extended use

up to 2 years
extended use

up to 1 year
extended use

Zero pregnancies

Zero pregnancies

Zero pregnancies

296.1

204.5

658.4

Women-Years
Observed

up to 2 years
extended use

0.24 per 100
women-years

Pregnancy
Outcomes

1 rod ENG

Brazil, Chile,
Dominican
Republic, Hungary, N= 390 with N=311 entering
Thailand, Turkey, 5th year and N=204
Zimbabwe
completing 5th year
1 rod ENG

Not discussed

N=100 with N=47
completing 4th year

1 rod ENG

Zero pregnancies 229.4
2 pregnancies- 1 in
the first month and
1 after 6 yrs. There
was 1 other
participant that was
pregnant prior to
insertion and she
was removed from
analysis.
823

Duration

Extended use up to 5 years of the
etonogestrel-releasing subdermal
contraceptive implant: comparison to
levonorgestrel-releasing subdermal
Multi-center, randomized
implant
clinical trial

Thailand

N=237 with N=123
completing 4th year and
N=34 completing 5th year

up to 1 year
extended use

Location

Non-randomized, noncomparitive, prospective
observational

US

N=249 with N=58 continued
into 6th and 7th years, N=5
did not return for removal
until 8th and 9th year
2 rod LNG

Not calculated

1 rod ENG

Ali M, Akin A, Bahamondes
L et al
2016
A 4-year pilot study on the efficacy
and safety of Implanon, a single-rod
hormonal contraceptive implant, in
healthy women in Thailand

Non-randomized,
comparitive, prospective
observational

US

644.6

N=200, N= 124 entering 4th
year and N=96 completing
4th year

Kiriwat O, Patanayindee A,
Koetsawang S et al
1998
Use of the etonogestrel implant and
levonorgestrel intrauterine device
beyond the U.S. Food and Drug
Administration-approved duration

Multi-center, nonrandomized, noncomparitive, prospective
observational

Zero pregnancies

A phase II study with a single implant
Affandi B, Korver T, Geurts P contraceptive containing 3Non-randomized, nonet al
ketodesogestrel (Implanon®):
comparitive, prospective
1999
Efficacy and safety
observational

McNicholas C, Maddipati R,
Zhao Q et al
2015

The levonorgestrel two-rod implant
for long-acting contraception: 10
years of clinical experience

up to 1 year
extended use

Strengths/Weaknesses

Quality

Poor

Fair

Poor

Fair

- Small population extending
duration
- Women self selected
extended duration
- No comparison group
Poor
- Age at enrollment was <35
years old
- Homogenous population
- Women self selected
extended duration
- Women self selected
extended duration
Poor
- Small population extending
duration
- Women self selected
extended duration
- No comparison group
Poor

- Small population extending
duration
- Women self selected
0 per 100 women- extended duration
years
- No comparison group
- Randomized clinical design,
however randomized to
contraceptive method NOT
0.6 per 100 women- extended duration
years [95 % CI: 0.2- - Multiple study sites
1.8]
- Comparison group
- Small population extending
duration
- Women self selected
extended duration
Not calculated
- No comparison group
- Assessed ancillary methods
of contraception (barrier
methods etc)
- Assessed comorbidities that
may affect fertility

Wan L, Stiber A, Lam L
2003

N=200 with N=157 entering
4th year and N=151
completing 4th year
1 rod ENG

Not reported

0 per 100 womenyears (one-sided
97.5% CI: 0, 1.61)

A long-term study of the efficacy and
Zheng S, Zheng H, Qian S et acceptability of a single-rod hormonal
al
contraceptive implant (Implanon) in Noncomparitive, multicenter
1999
healthy women in China
proscpective observational
China

Not reported

Not discussed

Zero pregnancies

Non-randomized,
comparitive, prospective
observational

up to 1 year
extended use

A randomized study comparing the
efficacy and bleeding pattern of
Implanon and Norplant hormonal
contraceptive implant

N= 75 with N=51 completing
the 4th year
1 rod ENG

Yao X and Du M
2003
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Discussion
Six published studies enrolling a total of 1,357 women and assessing extended
duration of a progestin contraceptive implant were identified, with only three reported
pregnancies, all among women using the LNG implant. Cumulative contraceptive failure
rates in these studies are far below the typical use failure rate of many popular userdependent methods such as oral contraceptive pills (1).
Pharmacokinetic studies of serum ENG are reassuring with regard to extended
duration of the ENG contraceptive implant. Prior work indicates that ovulation is
suppressed at serum ENG levels greater than 90 pg/mL (29). Women may exhibit wide
ranges of ENG, with some values below 90 pg/ml. Median ENG levels at the end of three
years of use of the implant are beyond this value at 207.7 pg/mL (range 63.8-802.6
pg/mL). Median serum ENG levels remain high at 166.1 pg/mL (range 25-470.5 pg/mL)
at four years of use and 153.0 pg/mL (range 72.1-538.8pg/mL) at five years of use (18).
Furthermore, McNicholas failed to show a difference in median serum ENG levels across
BMI groups, including obese women, at the end of the fifth year of implant use (18). A
similar pharmacokinetic study evaluated the minimum necessary LNG serum
concentration to prevent pregnancy. In this study, pregnancies were identified in five
women using the Jadelle® 2-rod LNG implant beyond five years. In all women, the
serum LNG levels fell to or below 180 pg/mL (30).
Importantly, the pharmacokinetic data on ENG and LNG has revealed that serum
concentrations between participants and even within the same participant over multiple
collections vary widely. It remains unclear what ENG level is needed to provide effective
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contraception, given the implant’s other mechanisms of action including cervical mucus
thickening and endometrial atrophy.
This systematic review has several limitations; results must be interpreted with
caution. All six studies are of poor to fair quality. Only one study randomized participants
to contraceptive method; no studies randomized participants to extended duration.
Participants who elected to extend duration may differ widely from those who chose not
to; important confounders such as risk of pregnancy were not addressed, raising concerns
of selection bias. Two studies separately analyzed contraceptive failures among women
within the extended duration; the other four analyzed cumulative pregnancy rates over
total duration of implant use. Sample sizes were relatively small (N=75 to 390) and loss
to follow up was high (25-86%). This could result in a falsely lowered pregnancy risk, as
pregnancies were diagnosed based on clinical concern at follow up appointments. Four of
the seven studies were industry sponsored. Few studies reported use of ancillary
contraception such as barrier methods as an exclusion criteria or reported additional
analysis to account for increasing participant age and possible decreased fecundity over
the study period. No studies were identified to inform guidance about the Sino-Implant II
or Nexplanon®. Inclusion and exclusion criteria for all studies defined participants as
medically healthy, limiting generalizability.
If found to be efficacious, the ability to extend duration of contraceptive implants
would serve to increase cost effectiveness of the device while decreasing barriers on
women by reducing the number of visits needed for implant removal and reinsertion.
While the findings of these studies report reassuring data for women considering
extended duration of implant use, more quality research is needed to confirm findings,
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guide clinical decision-making, and provide generalizable information to health programs
in different settings. Future research should attempt to address high participant attrition
and either engage in randomization of extended duration or critically evaluate potential
confounders in continuation. Future studies also need to address a variety of BMI
categories before conclusions can be made about overweight or obese women.
Additionally, more pharmacokinetic research is needed on ENG and LNG serum levels
as they relate to the outcome of interest: contraceptive failure.
Based on the current evidence, providers may consider the reassuring but limited
data on extension of the ETG implant by one year. However more high quality research is
needed before making generalized statements in support of extended duration. When
counselling individual women, providers must consider the context in which a woman
lives (e.g., access to health care, socio-economic situation), her medical history including
obesity and potential drug-drug interactions and the risk of an unintended pregnancy and
what it may mean to the woman. Together, in a shared decision making model they may
weigh risks against the benefits of her being able to extend the use of her implant.

Thaxton 46	
  
References
1.

Sundaram A, Vaughan B, Kost K, Bankole A, Finer L, Singh S, et al.

Contraceptive Failure in the United States: Estimates from the 2006-2010 National
Survey of Family Growth: contraceptive failure rates in the U.S. Perspect Sex Reprod
Health. 2017 Mar;49(1):7–16.
2.

Steiner MJ, Lopez LM, Grimes DA, Cheng L, Shelton J, Trussell J, et al. Sino-

implant (II) — a levonorgestrel-releasing two-rod implant: systematic review of the
randomized controlled trials. Contraception. 2010 Mar;81(3):197–201.
3.

Hatcher RA. Contraceptive technology. New York, N.Y.: Ardent Media; 2011.

4.

Spies EL, Askelson NM, Gelman E, Losch M. Young Women’s Knowledge,

Attitudes, and Behaviors Related to Long-Acting Reversible Contraceptives. Womens
Health Issues. 2010 Nov;20(6):394–9.
5.

Burns B, Grindlay K, Dennis A. Women’s Awareness of, Interest in, and

Experiences with Long-acting Reversible and Permanent Contraception. Womens Health
Issues. 2015 May;25(3):224–31.
6.

Bachorik A, Friedman J, Fox A, Nucci AT, Horowitz CR, Diaz A. Adolescent

and Young Adult Women’s Knowledge of and Attitudes Toward Etonogestrel Implants. J
Pediatr Adolesc Gynecol. 2015 Aug;28(4):229–33.
7.

Foster DG, Biggs MA, Malvin J, Bradsberry M, Darney P, Brindis CD. Cost-

Savings from the Provision of Specific Contraceptive Methods in 2009. Womens Health
Issues. 2013 Jul;23(4):e265–71.
8.

Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of

contraceptives in the United States. Contraception. 2009 Jan;79(1):5–14.

Thaxton 47	
  
9.

World Health Organization, Reproductive Health and Research, World Health

Organization. Medical eligibility criteria for contraceptive use. [Internet]. 2015 [cited
2017 Apr 25]. Available from:
http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf
10.

Bahamondes L, Bahamondes MV. New and emerging contraceptives: a state-of-

the-art review. Int J Womens Health. 2014 Feb;221.
11.

Turok DK, Gawron LM, Lawson S. New developments in long-acting reversible

contraception: the promise of intrauterine devices and implants to improve family
planning services. Fertil Steril. 2016 Nov;106(6):1273–81.
12.

Committee Opinion No. 670: Immediate Postpartum Long-Acting Reversible

Contraception. Obstet Gynecol. 2016 Aug;128(2):e32–7.
13.

Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, et al.

Current methods of the US Preventive Services Task Force: a review of the process. Am
J Prev Med. 2001;20(3):21–35.
14.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for

systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009 Jul
21;339:b2535.
15.

Safety,Effectiveness and Acceptability of Sino-implant II in DR - Full Text View

- ClinicalTrials.gov [Internet]. [cited 2017 Jul 27]. Available from:
https://clinicaltrials.gov/show/NCT01594632
16.

Nexplanon Observational Risk Assessment Study (NORA) - Full Text View -

ClinicalTrials.gov [Internet]. [cited 2017 Jul 27]. Available from:
https://clinicaltrials.gov/show/NCT01473641

Thaxton 48	
  
17.

Contraceptive Effectiveness of Sino-implant (II) in China - Full Text View -

ClinicalTrials.gov [Internet]. [cited 2017 Jul 27]. Available from:
https://clinicaltrials.gov/show/NCT01936454
18.

McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel

implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug
Administration–approved duration. Am J Obstet Gynecol [Internet]. 2017 Jan [cited 2017
Apr 27]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0002937817301710
19.

Zheng S-R, Zheng H-M, Qian S-Z, Sang G-W, Kaper RF. A randomized

multicenter study comparing the efficacy and bleeding pattern of a single-rod
(Implanon®) and a six-capsule (Norplant®) hormonal contraceptive implant.
Contraception. 1999;60(1):1–8.
20.

Affandi B, Korver T, Geurts TP, Bennink HC, Gadroen W. A phase II study with

a single implant contraceptive containing 3-ketodesogestrel (Implanon®): efficacy and
safety. Med J Indones. 1999;8(1):25.
21.

Rekers H, Affandi B. Implanon studies conducted in Indonesia. Contraception.

2004 Nov;70(5):433.
22.

Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended

use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant:
comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016
Nov;31(11):2491–8.
23.

McNicholas C, Maddipati R, Zhao Q, Swor E, Peipert JF. Use of the Etonogestrel

Implant and Levonorgestrel Intrauterine Device Beyond the U.S. Food and Drug
Administration–Approved Duration: Obstet Gynecol. 2015 Mar;125(3):599–604.

Thaxton 49	
  
24.

Wan L. The levonorgestrel two-rod implant for long-acting contraception 10

years of clinical experience. Obstet Gynecol. 2003 Jul;102(1):24–6.
25.

Kiriwat O, Patanayindee A, Koetsawang S, Korver T, Bennink HJ. A 4-year pilot

study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive
implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care Off J Eur
Soc Contracept. 1998 Jun;3(2):85–91.
26.

Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A long-term study of the

efficacy and acceptability of a single-rod hormonal contraceptive implant (Implanon) in
healthy women in China. Eur J Contracept Reprod Health Care Off J Eur Soc Contracept.
1999 Jun;4(2):85–93.
27.

Yao X, Du M. [A randomized study comparing the efficacy and bleeding pattern

of Implanon and Norplant hormonal contraceptive implant]. Zhonghua Fu Chan Ke Za
Zhi. 2003 Jul;38(7):419–22.
28.

Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The

Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception.
Am J Obstet Gynecol. 2010 Aug;203(2):115.e1–115.e7.
29.

Diaz S, Pavez M, Moo-Young AJ, Bardin CW, Croxatto HB. Clinical trial with 3-

keto-desogestrel subdermal implants. Contraception. 1991 Oct;44(4):393–408.
30.

Sivin I, Wan L, Ranta S, Alvarez F, Brache V, Mishell DR, et al. Levonorgestrel

concentrations during 7 years of continuous use of Jadelle contraceptive implants☆.
Contraception. 2001;64(1):43–9.

Thaxton 50	
  

CHAPTER 3
A Randomized Controlled Trial of Nitrous Oxide for Intrauterine Device
Insertion in Nulliparous Women
Introduction
Intrauterine devices (IUDs) provide safe, highly effective, and convenient
reversible long-term contraception. Despite these advantages, IUDs were used by less
than 3.6% of women aged 15–19 years in 2006–2008 in the USA (1). Fear of pain during
IUD insertion is a barrier for adolescents and nulliparous women (2). Additionally,
clinicians could be reluctant to offer IUDs to nulliparous women, whom they believe
experience more pain with IUD insertion (3,4). Because cervical cytology for cancer
screening is now deferred until the age of 21 years in the USA (5), and urine testing is
often used for sexually transmitted infection screening (6), few young nulliparous women
have undergone a pelvic examination. Fear of discomfort associated with such an
examination could compound the fear of pain from IUD insertion. Nulliparous women
experience moderate pain with IUD insertion (7–9). Misoprostol, non-steroidal antiinflammatory drugs, and local anesthesia have been studied, but not shown to reduce IUD
insertion pain among nulliparous women (10–12). Identification of effective interventions
to reduce the pain of IUD insertion for nulliparous women could promote acceptability
and utilization.
Nitrous oxide titrated with oxygen (N2O/O2) is an inhalation agent that affords
safe, effective, non-invasive analgesic and anxiolytic with rapid onset and clearance (13).
It has a favorable adverse effects profile, and has been used for many years with excellent
outcomes for procedural analgesia and anesthesia in outpatient clinics, including
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dentistry and emergency department settings (14–16). N2O/O2 is attractive in the clinic
because delivery systems are fairly inexpensive, training is not burdensome, and
administration of the gas is noninvasive. To our knowledge, no studies have evaluated the
use of N2O/O2 for IUD insertion among nulliparous women.
The primary objective of the present study was therefore to determine whether
N2O/O2 at a 50%/50% concentration decreases pain as compared with oxygen alone
(O2) during IUD insertion among nulliparous women who choose a 52-mg levonorgestrel
or copper T380A IUD.

Materials and methods
A randomized, double blinded, placebo-controlled trial of N2O/O2 versus O2 for
IUD insertion was conducted among nulliparous women attending the Center for
Reproductive Health clinic at the University of New Mexico, Albuquerque, NM, USA,
between October 1, 2013, and August 31, 2014. English-speaking nulliparous women
aged 13–45 years who chose the 52-mg levonorgestrel or copper T380A for
contraception were recruited. Women were included if they had never been pregnant or
had not carried a pregnancy beyond 19 weeks and 6 days, were at least 4 weeks from the
end of a pregnancy, and had a negative urine pregnancy test. Women younger than 18
years were eligible if accompanied by a parent or legal guardian who signed the
informed consent. Participants were excluded if they were actively using prescribed
opioids, benzodiazepines or illicit drugs, or had contraindications to IUD insertion or
N2O/O2 administration, including respiratory infection, chronic obstructive pulmonary
disease, intoxication, or inability to breathe through the nose. The University of New

Thaxton 52	
  
Mexico Health Science Center Human Research Review Committee approved the study
(ref. no. 13-289) and all participants provided written informed consent before study
participation.
Study team members recruited participants on the day of the IUD insertion
procedure. Participants received routine clinical and preprocedural care and counseling.
After providing informed consent, participants were randomly assigned to one of two
groups via a randomization scheme in blocks of four, computer-generated by a
statistician not involved in study recruitment. Randomization allocation was concealed in
sequentially numbered opaque envelopes. Each envelope was opened by the person
administering the inhalation agent immediately before the procedure, and the contents
were not seen by other clinicians. A disposable scented nasal mask was fitted
for all patients to ensure they were not aware of group assignment. The biostatistician
was not masked to group assignment during data analysis.
A dedicated physician or nurse administered N2O/O2 or O2 for 2 minutes, as per
the randomization assignment, before the IUD insertion procedure. The N2O/O2 delivery
system was concealed behind a screen to maintain masking of both the patient and the
clinician performing the IUD insertion. N2O/O2 was titrated up to a fixed dose ratio of
50%/50% N2O/O2 before the IUD procedure; 100% O2 was used in the control group.
The control group did not receive any other medication. Participants were monitored for
level of consciousness, ventilation status, and oxygenation during administration of the
inhaled gas.
The IUD insertion procedure was similar for all participants. A bimanual
examination was performed before speculum insertion. The cervix was cleansed with an
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antiseptic solution. A single-tooth tenaculum was placed on the cervix and a uterine
sound was used to measure cavity length. The IUD was inserted via a standard insertion
technique as described in the package leaflet. The bimanual examination denoted the
beginning of the procedure and removal of the speculum marked the end.
The participants assessed their baseline pain, expected pain, IUD insertion pain,
and pain at the time of discharge from the clinic via a 100-mm visual analog scale (VAS;
0 mm indicated no pain, 100 mm pain as bad as it can be). The primary pain outcome was
maximum pain with IUD insertion assessed 2 minutes after completion of the procedure,
which is the timepoint at which N2O/O2 is expected to be systemically cleared.
Satisfaction with pain management during IUD insertion was assessed with a five-point
Likert scale (very satisfied, satisfied, neutral, dissatisfied, and very dissatisfied) and 100mm VAS (0 mm indicated very dissatisfied, 100 mm very satisfied). Women who
reported being dissatisfied were able to describe in free text the reason why they were
dissatisfied with their pain management. The physician who inserted the IUD recorded
the procedure details and assessed the difficulty of IUD insertion on a 100-mm VAS (0
mm, very easy; 100 mm, most difficult). Physicians were also asked to guess whether the
patient had received N2O/O2 or 100% O2. Participants completed a demographic and
medical history questionnaire before the procedure. Before discharge from the clinic,
women also completed a questionnaire regarding their IUD insertion experience, which
included a question asking them to guess whether they had received N2O/O2 or 100%
O2. All participants received a US$10 gift card for a local retail shop to compensate for
the inconvenience of the study procedures.
Sample size was based on the assumption that a 15-mm difference on a 100-mm
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VAS is the minimal clinically important difference in pain (17). In previous studies,
mean pain scores (measured on a 100-mm VAS) for IUD insertion among nulliparous
Hispanic and non- Hispanic white women were 61.9±25mm (8) and 55±21mm (7),
respectively. Because the New Mexico population consists of primarily non-Hispanic
white and Hispanic women, a pooled standard deviation (SD) of 23 was assumed. To
detect a 15-mm difference in pain scores between the N2O/O2 and O2 groups with an SD
of 23, a sample size of 38 women per treatment group was necessary with a β value of
0.80 and an α value of 0.05. With an anticipated 5% drop out rate after randomization,
the recruitment goal was established at 40 women per group.
Study data were collected and managed using Research Electronic Data Capture
(REDCap) (18). Different research coordinators entered the study data into the Double
Data entry feature in REDCap to compare data entry results via the data comparison tool.
SAS version 9.3 (SAS Institute, Cary, NC, USA) was used for all data analyses.
Data were analyzed by intention to treat. Normally distributed continuous
variables were compared by parametric tests (t test and analysis of variance), and
continuous variables that were not normally distributed were compared by nonparametric Wilcoxon-rank sum tests. Categorical variables were compared by Fisher
exact test. P<0.05 was considered to be statistically significant.

Results
Among 161women evaluated for enrollment, 93 (58%) were eligible (Figure 1).
Of the 93 eligible women, 80 (86%) were enrolled; 40 were allocated to each group. The
IUD insertion procedure was discontinued for one participant in the N2O/O2 group

Thaxton 55	
  
owing to the creation of a false tract, but she was included in the analysis (Figure 1).
Fig. 1. Flow of patients through the study.
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The mean age of participants was 25.6 ± 5.8 years. Most women were single (52
[65%] participants), and were predominantly non- Hispanic white (43 [54%]) and
Hispanic (29 [36%]). Most women had completed some college or were college
graduates (73 [91%]), and most were employed either part- or full-time (63 [79%]). Most
participants earned less than US$40 000 per year (51 [64%]). Characteristics of women in
the N2O/O2 group were similar to those of the participants assigned to the O2 group
(Table 1).
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Mean insertion pain scores at IUD insertion were similar among the N2O/O2 and
O2 groups (P=0.86) (Table 2). Baseline and expected pain, and pain at the time of
discharge from the clinic were also similar between the two groups (Table 2). The 52-mg
levonorgestrel IUD was selected by 67 (84%) participants. Mean insertion pain score was
57.5 ± 21.7 mm with the 52-mg levonorgestrel IUD and 43.4 ± 23.0 mm with the copper
T380A IUD (P=0.07).
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Use of adjunctive measures—e.g. the os-finder and dilators—was more common
in the N2O/O2 group than in the O2 group (P=0.02), whereas the procedure duration did
not differ between the two groups (P=0.14) (Table 3). The obstetrics–gynecology faculty,
family medicine faculty, and family planning fellows inserted all IUDs, with most
inserted by the obstetrics–gynecology faculty (46 [58%]). Pain scores did not differ
among the provider types (data not shown). One (3%) IUD insertion procedure was
unsuccessful within the N2O/O2 group owing to the creation of a false tract.
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Satisfaction with pain management was similar between theN2O/O2 and O2
groups (P=0.39) (Table 2). Significantly more women in the N2O/O2 group than in the
O2 group were satisfied with their pain management on the Likert scale (P=0.04) (Table
2). Women reported their dissatisfaction with pain management as follows: “It hurt more
than I expected;” “There needs to be better options for pain management;” and “I felt
there was little to no pain control.”
The frequency of adverse effects did not differ by group (P=0.32) (Table 3).
Three (8%) women in the N2O/O2 group experienced dizziness, and 5 (13%) in the O2
group reported nausea.
Irrespective of the randomization group, most women reported that they would
choose an IUD for contraception again in the future, and most would choose N2O/O2 for
pain management during the insertion procedure (data not shown). Notwithstanding the
discomfort of the procedure and irrespective of group, most women would also
recommend the IUD to a friend and would recommend N2O/O2 for IUD insertion (data
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not shown). Overall, 50 (63%) participants reported that they would be willing to pay an
additional US$20–$50 to receive N2O/O2 during the insertion procedure.
Physicians correctly identified the gas assignment for approximately 19 (48%)
women receiving N2O/O2 and 24 (60%) of those receiving O2. Most women in the O2
group (38 [95%]) correctly identified receiving O2, and only half (21 [53%]) correctly
identified receiving N2O/O2.

Discussion
In the present study, nulliparous women experienced pain with IUD insertion, and
inhaled N2O/O2 made the participants more satisfied with the insertion process although
their pain was not reduced. The finding of no reduction in pain with N2O/O2 could
reflect the use of a suboptimal concentration of N2O/O2, which was fixed at 50% N2O
and 50% O2. One distinct advantage of N2O/O2 is that it can be titrated in incremental
doses quickly until a patient has reached a comfortable, relaxed state of sedation. By
using a fixed proportion, the dosing of N2O/O2 was not optimized to the individual
patient needs. The N2O/O2 delivery system that was used includes a scavenging vacuum
system on the mask, which might also negatively affect the concentration of gases
delivered. For a brief gynecologic procedure lasting only a few minutes, a higher ratio—
e.g. 70%/30% N2O/O2, as used for dental procedures—might be more effective.
The primary outcome of the study was assessed at 2 minutes after the procedure
when the effects of N2O/O2 would have dissipated. Past experience using N2O/O2 at the
study institution has indicated that an assessment of pain during IUD insertion while the
patient is under the influence of N2O/O2 could yield different results.
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The signs and symptoms of N2O/O2 sedation are very apparent and therefore
could have affected the ability of the outcome assessors to be truly masked to the
patient’s intervention assignment. The present results suggest that physicians and
participants correctly identified participants receiving N2O/O2 in slightly more than 50%
of cases.
Women who received N2O/O2 were more satisfied with their pain management.
This finding is consistent with the manner in which N2O/O2 works as an analgesic (via
mediation of release of endogenous opioids) (19) and anxiolytic (via modulation of
GABA receptors) (20). A similar finding of increased patient satisfaction with pain
management, despite an insignificant reduction in pain, has also been demonstrated
when N2O/O2 is used for labor analgesia (21) and for first-trimester surgical abortion
(22).
The strengths of the study include the double-blind, placebo controlled,
randomized design; the ethnic diversity of the participants; and the use of N2O/O2 as an
intervention. Once the initial expense of installing a N2O/O2 system has been met, the
ongoing costs of N2O/O2 administration and training are manageable for small clinics.
Furthermore, N2O/O2 has minimal adverse effects and quickly dissipates from the body,
obviating the need for post-procedure monitoring.
The limitations of the study include limited external generalizability, fixed dosing
of N2O/O2, and use at a high altitude (Albuquerque is approximately 1600 m above sea
level), which decreases the effect of N2O/O2. Other limitations could include timing of
pain assessment, and limited ability to truly mask outcome assessors and patients to
the effects of N2O/O2. The study was conducted at an academic family planning center
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where all insertions were performed by faculty and family planning fellows who
frequently insert IUDs in nulliparous women. Overall, the IUD insertion pain scores in
the study were lower than those reported in other studies (7,8).
In conclusion, women desire an intervention to help reduce the pain of IUD
insertion and, on the basis of the present study, N2O/O2 has the potential to improve the
experience of pain by increasing satisfaction with pain management. Higher
concentrations of N2O and titration of the ratio to an individual’s needs could further
improve the experience of nulliparous women with IUD placement. It could also be
valuable to explore N2O/O2 for pain management of other office-based gynecologic
procedures.
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CHAPTER 4
Nitrous Oxide versus Intravenous Sedation for Anesthesia: A Randomized Clinical Trial
Introduction
Pain management is an important component of patient-centered abortion care.
Of the estimated annual 926,200 abortions in the United States, 96% occur in the office
setting with limited anesthesia options (1). Second trimester abortion is painful and
commonly performed with use of intravenous (IV) sedation with midazolam and
fentanyl for analgesia (2). Data is sparse about what constitutes an ideal anesthetic for
this procedure. Many clinics administering IV sedation require women to fast prior to the
procedure and bring a chaperone to drive them home, (3) a burdensome requirement for
women who may travel long distances and need or desire to maintain privacy. The ideal
anesthetic for second trimester abortion would effectively control abortion pain, maintain
patient safety, be easily administered, and have rapid onset and clearance.
Nitrous oxide (N2O/O2) offers analgesia, anxiolysis and amnesia, has immediate
onset of action and dissipates rapidly (4)(5)(6). Its safety and efficacy have been
established for dentistry, emergency department procedures and vaginal delivery (7)(8).
Few studies have examined nitrous oxide for sedation in outpatient gynecologic
procedures. Prior research has not found pain reduction in first trimester abortion when
utilizing nitrous oxide as an adjuvant treatment at lower concentrations (9)(10). However,
one prior study evaluated nitrous oxide alone at an increased titration schedule (70%
nitrous:30% oxygen) compared to oral sedation for first trimester surgical abortion with
similar mean pain scores (11). In the setting of transcervical sterilization procedures,
nitrous oxide has been shown to be superior to oral sedation (12).
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In this multisite, double blinded, randomized clinical trial, we investigated
whether nitrous oxide was a non-inferior alternative to IV sedation for pain management
in surgical abortion between 12 and 16 weeks. Our primary outcome was the difference
between the groups in maximum abortion pain, measured as means on a Visual Analog
Scale (VAS). We hypothesized that the VAS pain scores of participants receiving nitrous
oxide would be non-inferior to those of participants receiving IV sedation.

Materials and Methods
From August 2016 to March 2017, eligible women were recruited from the
University of New Mexico and the University of Colorado reproductive health clinics.
These are both University-based clinical practices with a focus on complex contraception
and abortion care and are responsible for training Ob/Gyn family planning fellows.
Eligible women were over age 18, between 12 and 16 weeks gestational age by
best obstetrical dating, English or Spanish speaking, and able to obtain a ride home
following the procedure. Exclusion criteria were clinical contraindications to outpatient
abortion such as invasive placentation or significant medical comorbidities, or
contraindications to nitrous oxide such as active upper respiratory tract infection, chronic
obstructive pulmonary disease and current treatment with bleomycin chemotherapy.
Additional exclusion criteria were intrauterine fetal demise, chronic narcotic use or prior
adverse reactions to any of the study drugs. Microsoft Excel was utilized to create a
randomization list with a block randomization scheme and stratification by gestational
age in weeks.
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After women decided to proceed with outpatient abortion and gave appropriate
informed consent, research staff approached and enrolled prospective participants.
Cervical preparation occurred at the treating physician’s discretion and included
intracervical dilators and/or misoprostol. Participants were randomized to IV sedation or
nitrous oxide immediately prior to the abortion procedure. The anesthesia provider
opened the appropriate opaque envelope to determine the allocation. All participants
received 600mg of ibuprofen, IV access and a scented face mask worn for the duration of
the procedure. Participants were positioned for the procedure and the unblinded
anesthesia provider administered allocated study medications at least two minutes prior
to starting the procedure. The IV sedation group received 100 mcg of fentanyl and 2 mg
midazolam IV, and 100% oxygen via face mask; those allocated to nitrous oxide received
IV saline, and were titrated to 70% nitrous oxide:30% oxygen via face mask. All
participants received a standardized paracervical block of 20 cc of buffered lidocaine,
with 1-2 cc at the tenaculum site, and 18 cc divided equally at the 4 and 8 o’clock
cervicovaginal junction (13). If a participant needed further pain medication during the
procedure, based on participant response or physician assessment, those in the IV
sedation group received additional IV sedation medications and those in the nitrous oxide
group received 100 mcg of fentanyl and 2 mg midazolam IV after discontinuation of the
nitrous oxide and more IV sedation medications as needed according to clinic protocol. In
the event of over-sedation, all members of the team were to be unblinded and appropriate
resuscitative measures initiated.
The abortion procedure technique followed clinical standard of care, and was not
altered for the study; details of the procedure including duration, use of mechanical
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dilation, cannula size and use of forceps was recorded. Immediately following the
procedure and while still receiving the allocated medication, participants rated their
maximum pain on the VAS. Following the procedure, nurses monitored participants until
they achieved an Alderete score of 8 or greater (14). At 30 minutes post-procedure,
participants completed another VAS, recalling maximum abortion pain. To maintain
masking, all procedural data were entered into a Research Electronic Data Capture
(RedCap) database (15) by study coordinators, while medication information was entered
separately by the anesthesia provider or research pharmacist.
The primary study outcome was immediate recall of maximum procedural pain on
the VAS. In the only study of pain during second trimester abortion, median pain for
expulsion of the fetus during medical induction with or without IV fentanyl was 70mm
(IQR 50, 80) (16). We used this value to calculate sample size using a 1-sided, 2-group
test of non-inferiority and determined that a sample size of 76 participants with 38 per
treatment group, could detect a non-inferiority margin of 15mm with 90% power and
type 1 error of 5%.
A data safety monitoring board (DSMB) was created along with pre-determined
study stopping rules. This DSMB of external reviewers knowledgeable in family
planning and abortion care, not involved in the study, planned to review data after each
quarter of participants was enrolled. Prior clinical data from the University of Colorado
demonstrated that 24% (+/-7% [CI 95%]) of women undergoing abortion in our target
gestational age received additional IV pain medication. Based on this percentage, we
created a stopping rule to halt the study and conduct a full data and safety review if more
than 35% of women in either group required additional pain medication.
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Nonparametric Wilcoxon rank sum tests were used for non-normally distributed
continuous data, tests of proportions were used to assess binomial outcomes and Pearson
χ2 tests were used for categorical variables. Both intention-to-treat (ITT) and per protocol
analysis were performed with per-protocol analyses only reported if findings were
different from ITT (17) (18). Women requiring additional pain medication were then
considered a separate group and median pain scores analyzed by one way Kruskal-Wallis
test. Sample size calculations were performed and data were analyzed using STATA/SE
14.1 (2015), StataCorp LP, College Station, TX, USA.
The institutional review boards at the University of New Mexico Health Sciences
Center and the University of Colorado approved this study.

Results
Of 170 participants assessed for eligibility, 39 were enrolled and randomized: 19
to the nitrous group and 20 to the IV sedation group. Eligibility was assessed and is
reported per CONSORT guidelines (Figure 1). One participant within the nitrous group
did not receive her allocated intervention due to equipment failure. No women in the IV
sedation group required additional pain medications. Seven women in the nitrous group
(37%) underwent conversion to IV sedation because they required additional pain
medication, as determined by the patient and/or the physician. This percentage exceeded
our predefined stopping rule of 35%. Enrollment was halted by the DSMB and data were
analyzed.
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Figure 1: Study Flow Diagram
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Baseline participant demographic and procedural characteristics were similar
between the two study groups (Tables 1 and 2). The median age of the cohort was 26
years (range 18-42 years), and just over half of women were parous. Participants
represented a diversity of ethnicities consistent with the populations of the two study
sites. Participants were recruited evenly from both locations and almost all procedures
were performed by an Ob/Gyn attending physician or family planning fellow (95%
nitrous group, 95% IV sedation group). Most procedures required cervical preparation
with misoprostol, osmotic dilators, or both and most were completed on the same day
(84% nitrous group, 78% IV sedation group).
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Table 1: Baseline Participant Characteristics
Characteristics
Age (yrs)*
Prior birth outcomes‡
Vaginal Births
C-Section Births
Abortions
Miscarriages
Stillbirth
None (Nulliparity)
Ethnicity
Hispanic
Race
White
Black or African American
American Indian/Alaska Native
Other including mixed
Relationship status
In a committed relationship
Education
High school or equivalent
More than high school
Bachelor’s or graduate degree
Gestational age
12
13
14
15

N2O/O2
N= 19
(frequency, %)
27 (22, 34)

IV Sedation
N = 20
(frequency, %)
26 (20, 29)

10 (53)
6 (34)
7 (37)
5 (26)
1 (5)
3 (16)

11 (55)
2 (10)
5 (25)
8 (40)
0 (0)
8 (40)

10 (53)

9 (45)

8 (42)
4 (21)
1 (5)
6 (32)

8 (40)
0 (0)
3 (15)
9 (45)

13 (68)

13 (65)

8 (42)
8 (42)
3 (16)

8 (40)
9 (45)
2 (15)

8 (42)
3 (16)
5 (26)
3 (16)

8 (40)
4 (20)
5 (25)
3 (15)

*Age reported in Median (Interquartile range).
‡Values do not total to 100% to reflect multiple birth outcomes per participant.
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Table 2: Procedure Information
Characteristic
Provider
Ob/Gyn Attending
Family Practice Attending
Family Planning Fellow
Location
UNM
CO
Cervical prep
Misoprostol
Osmotic dilators
Length of prep
One day

N2O/O2
N= 19
(frequency, %)

IV Sedation
N = 20
(frequency, %)

7 (37)
1 (5)
11 (58)

10 (50)
1 (5)
9 (45)

11 (58)
8 (42)

12 (60)
8 (40)

15 (79)
5 (26)

13 (76)
8 (40)

16 (84)

14 (78)

In intent-to-treat analysis, immediate VAS pain scores were analyzed using least
squares means to prove inferiority: pain scores were lower among women randomized to
IV sedation by 20.1 mm (95% CI 1.6 to 38.6), a value which is beyond our a priori
inferiority margin of 15 mm (Figure 2).
Figure 2: Mean Maximum Procedural Pain (along the VAS in mm)

In per-protocol analysis, this effect was no longer significant. In order to separate
and evaluate the pain scores of those women that had been converted from nitrous to IV
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sedation, the groups were then divided into three categories: IV sedation, nitrous sedation
and those that were converted to IV sedation. Due to the small size of the populations and
non-normal distributions, nonparametric analysis was performed with immediate postabortion median (Q1, Q3) pain scores of 29 mm (16, 49), 30 mm (15, 78) and 67 mm (60,
75) respectively (p <0.05) (Figure 3).
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Figure 3: Maximum Procedure Pain
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Table 3: Pain Scores (as reported by VAS in mm)

Baseline

N2O/O2
N= 19
(median, IQR)
3 (1, 11)

IV Sedation
N = 20
(median, IQR)
2 (0, 22)

Expected

49 (35, 78)

54 (20, 70)

NS

61 (30, 78)

28 (16, 49)

0.03

66 (38, 88)

17 (6, 40)

0.001

Pain Time point

Maximum experienced
(immediate recall)
Maximum experienced*
(recall prior to leaving
clinic)
*N=18 in N2O/O2 group

p-value
NS

Similar to immediate post-abortion pain scores, the median (Q1, Q3) VAS scores
for recall of maximum abortion pain prior to discharge from the clinic were lower among
women randomized to IV sedation; 66 mm (38, 88) in the nitrous group, and 17 mm (6,
40) in the IV sedation group (Table 3). Duration of the procedure was longer among
women randomized to nitrous oxide: 14 minutes (11, 17) in the nitrous group, and 10
minutes (8, 12) in the IV sedation group. When analyzed by allocation received, it
became apparent that the longer times were due to conversion from nitrous to IV
sedation. Participants reported few side effects; one noted nausea and five bled to the
point of requiring additional medications (not different between groups). No women in
either group became over sedated.

Discussion
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Under our experimental conditions, nitrous oxide was inferior to IV sedation for
pain control in 12-16 week abortion care. Few women experienced side effects of nitrous
oxide and no women became over sedated.
We chose to investigate nitrous oxide as an anesthetic agent for this procedure
because of perceived benefits to both clinics and patients. Nitrous oxide is an appealing
agent for use in the clinic as delivery systems are relatively inexpensive and training is
not burdensome. Benefits to the patient include rapid reversibility with administration of
100% oxygen and noninvasive delivery of the gas (5)(6). When evaluating the quality of
the abortion care experience, women value both pain control and privacy (19); an
effective rapidly reversible medication provides both.
Strengths of this study included its randomized controlled design with multi-site
recruitment. We used validated metrics to evaluate pain with anesthesia. Limitations of
the study included use of nitrous oxide in the high altitude cities of Albuquerque and
Denver, where the analgesic effect may be reduced (20). Additionally, pain scores from
prior studies was not consistent with pain scores identified in this study. Our assumptions
were based on second trimester medical pregnancy termination with IV fentanyl, (16)
since no studies had established mean pain scores among women during a second
trimester surgical abortion procedure. Pain scores for second trimester surgical abortion
in this study were much lower than those reported with medical termination of
pregnancy.
We found nitrous oxide to be an inferior method of anesthesia compared to IV
sedation for 12-16 week surgical abortion, however future studies should continue to
search for a patient-centered quality anesthetic to provide alternative options for women.
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CONCLUSION
The enclosed primary studies were designed to investigate avenues for improving
the delivery of family planning care per the Institute of Medicine’s quality principles.
Through systematic review of the existing literature, there is not sufficient evidence to
change recommendations for contraceptive implant duration for all women. However,
young, healthy women of normal body mass index should have the opportunity to extend
use in consultation with their provider. This information is currently under review with
the World Health Organization (WHO) and providers should await their final
recommendations for further guidance. Nitrous oxide did not improve the experience of
pain with IUD insertion or second trimester abortion. This method of anesthesia was
chosen for its rapid clearance, allowing women to fit family planning care into their daily
lives with convenience and confidentiality. Future studies should investigate novel
anesthetic agents with similar rapid clearance properties. While there is still much to be
learned about the medical community’s ability to increase the quality of care rendered,
these studies add to the growing body of literature on patient-centered health care
delivery.

